Of the total number of subjects [N=3884] in Phase II and III clinical studies of
Sitagliptin, 725 patients were 65 years and over, while 61 patients were 75 years and older. No overall differences in safety or effectiveness were observed between subjects 65 years and over and younger subjects. While this and other clinical experience have not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out.